Introduction
============

Lipid oxidation products are formed by free radicals *in vivo* \[[@B1]--[@B4]\]. Recently, various lipid oxidation products (such as phosphatidylserine hydroperoxide, cardiolipin hydroperoxide, 4-hydroxy-2-nonenal and 8-isoprostane) have attracted much attention as signaling molecules \[[@B5]--[@B11]\]. For example, phosphatidylserine hydroperoxide \[[@B5], [@B11]\] and cardiolipin hydroperoxide \[[@B5], [@B6]\] participate in the apoptotic process. We have previously reported that diacylglycerol (DAG) hydroperoxide (DAG-OOH), mainly dilinoleoylglycerol hydroperoxide, activated rat brain protein kinase C (PKC) \[[@B12]\] as strongly as 4β-phorbol-12β-myristate-13α-acetate (PMA), a powerful PKC activator \[[@B13]\]. DAG-OOH would be formed via the hydrolysis of phospholipid hydroperoxide by the action of phospholipase C (PLC) \[[@B14]\]. Oxidized phospholipids are formed by the oxidation of membrane phospholipids, since lipids are vulnerable to free radical-induced oxidation \[[@B15]\]. This process is unregulated since it does not mediate a receptor in the biomembrane. PMA induces various diseases, such as cancer, via PKC activation \[[@B16], [@B17]\], but it is not a physiological molecule. Therefore, DAG-OOH is expected to work as a physiological PKC activator, which induces oxidative stress-related diseases (such as cancer, inflammatory disease, autoimmune disease, and atherosclerosis) \[[@B15]\].

We have also reported that 1-palmitoyl-2-linoleoylglycerol hydroperoxide (PLG-OOH) induced superoxide (O~2~^·−^) production by human peripheral neutrophils \[[@B18]\]. Since other molecular species of DAG-OOH can be formed in the biological systems, it is important to confirm which molecular species of DAG-OOH activates neutrophils. O~2~^·−^ is produced by human neutrophils via both PKC-dependent and -independent pathways \[[@B19], [@B20]\]. Therefore, we examined which pathway occurred in DAG-OOH-stimulated PMNs. PKC inhibitors, such as chelerythrine, staurosporine, and H-7, suppressed the production of O~2~^·−^ from neutrophils activated by DAG-OOH \[[@B18]\], but this is indirect evidence. Since p47^*phox*^, a cytosolic component of NADPH oxidase, is phosphorylated by PKC when O~2~^·−^ is generated from neutrophils, the detection of phosphorylated p47^*phox*^ is direct evidence for PKC activation in neutrophils \[[@B21]\]. If phosphorylation of p47^*phox*^ is observed in DAG-OOH-stimulated neutrophils, it indicates the activation of PKC in neutrophils by DAG-OOH.

In the present study, we investigated which molecular species of DAG-OOH activate human peripheral neutrophils and the phosphorylation of p47^*phox*^ in neutrophils stimulated by DAG-OOH.

Materials and Methods
=====================

Materials
---------

1-Palmitoyl-2-linoleoyl-phosphatidylcholine, 1-stearoyl-2-linoleoyl-phosphatidylcholine, 1-palmitoyl-2-arachidonoyl-phosphatidylcholine, 1-stearoyl-2-arachidonoyl-phosphatidylcholine, 1,2-dioleoylglycerol (OOG), and 1-oleoyl-2-acetylglycerol (OAG) were purchased from Funakoshi Co. Ltd. (Tokyo, Japan). PMA, *N*-formyl-methionyl-leucyl-phenylalanine (fMLP), *bacillus cereus* PLC (type IX), and soybean lipoxygenase (type 1B) were obtained from Sigma Chemical Co. (St. Louis, MO). 2-Methyl-6-(*p*-methoxyphenyl)-3,7-dihydroimidazo \[1,2-*a*\] pyrazin-3-one (MCLA) was obtained from Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan). Chelex®100 was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). \[^32^P\]-Orthophosphoric acid was purchased from NEN Life Science Products, Inc. (Boston, MA). Solvents and other reagents were of the highest grade available. Rabbit polyclonal anti-p47^*phox*^ antibody was from Dr. Naoki Okamura (Hiroshima University School of Medicine) \[[@B22]\].

Preparation of various molecular species of diacylglycerol, their hydroperoxides and their hydroxides
-----------------------------------------------------------------------------------------------------

Various molecular species of DAG, DAG-OOH and DAG hydroxide (DAG-OH) were prepared as previously reported \[[@B18]\] with some modifications. Phosphatidylcholine (PC) was purified using reversed-phase HPLC prior to use. PC (6 µg) was oxidized with lipoxygenase (2.6 mg) in 0.2 M borate buffer treated with Chelex 100 (pH 9, 20 ml) containing 3 mM sodium deoxycholate for 20 min by mixing vigorously at room temperature under air. If necessary, sodium borohydride was added to the reaction mixture to reduce the phosphatidylcholine hydroperoxide (PC-OOH) after the reaction was over. Solid phase extraction was performed with a Sep-Pak C18 cartridge (10 g, Waters Co., Milford, MA), which was pretreated with 100 ml of 100 µM EDTA aqueous solution. The reaction mixture containing PC-OOH or PC hydroxide (PC-OH) was applied to the cartridge after it was equilibrated with 100 ml of water. PC-OOH or PC-OH was eluted with 100 ml of methanol after washing with 200 ml of water. PC-OOH or PC-OH was purified with reversed-phase HPLC after the eluate was concentrated with a rotary evaporator, and it was filtered with a 0.22 µm filter (MILLEX®-GP; Millipore Co., Bedford, MA). The PC, PC-OOH, or PC-OH was hydrolyzed by PLC in 50 mM Tris-HCl (pH 7.4) containing 40% methanol at 37°C. The reaction was monitored with HPLC. The DAG, DAG-OOH or DAG-OH formed was extracted with chloroform/methanol (2/1, by volume) three times. After the concentration of the collected lower layer using a rotary evaporator, DAG, DAG-OOH or DAG-OH was purified by HPLC with a CAPCELPAK C18 column (type: UG120, 20 × 250 mm, 5 µm, Shiseido Co. Ltd., Tokyo, Japan) and methanol/2-propanol (=17/3, by volume) as the mobile phase at a flow rate of 10 ml/min. Their elution times were as follows; 15.8 min (PLG), 20.5 min (1-stearoyl-2-linoleoylglycerol; SLG), 15.5 min (1-palmytoyl-2-arachidonoylglycerol; PAG), 19.0 min (1-stearoyl-2-arachidonoylglycerol; SAG), 14.5 min (1,3-dilinoleoylglycerol; 1,3-LLG), 9.3 min (PLG-OOH), 10.5 min (SLG-OOH), 9.3 min (PAG-OOH), 10.5 min (SAG-OOH), 8.5 min (1,3-LLG-OOH), 9.3 min (PLG hydroxide; PLG-OH), 10.3 min (SLG-OH), 9.3 min (PAG-OH) and 10.8 min (SAG-OH). DAG was monitored at 215 nm. DAG-OH or DAG-OOH was monitored at 234 nm. The concentration of DAG-OOH was determined using a hydroperoxide-specific, isoluminol chemiluminescence assay \[[@B23]\]. The absence of hydroperoxide in DAG-OH and DAG was also confirmed using this assay. The concentration of DAG-OH was estimated from its absorbance at 234 nm using an assumed molar extinction coefficient, 28,000 M^−1^cm^−1^ \[[@B24]\]. The concentration of DAG was calculated from their weights.

Measurement of MCLA-dependent chemiluminescence
-----------------------------------------------

Blood was drawn from healthy volunteers. Neutrophils were prepared as described previously \[[@B18]\]. A glass cuvette containing neutrophils (5.0 × 10^4^ cells) and 2 µmol of MCLA in 1,990 µl of Hanks' balanced salt solution containing 1.3 mM calcium ion and 0.9 mM magnesium ion was incubated at 37°C for 3 min under air. Thereafter, 10 µl of a stimulator, such as 800 µM or 1.6 mM DAG, DAG-OOH, or DAG-OH, or 200 µM fMLP dissolved in methanol, was added to the reaction mixture using a microsyringe. MCLA-dependent luminescence (O~2~^·−^ production \[[@B25]\]) was recorded using a luminescence reader (type: BLR-301, Aloka Co. Ltd., Tokyo, Japan).

Detection of phosphorylated p47^phox^
-------------------------------------

Neutrophils were suspended in calcium ion, phosphate-free buffer (10 mM HEPES, 137 mM sodium chloride, 5.4 mM potassium chloride, 5.6 mM D-glucose, 0.8 mM magnesium chloride, and 0.025% BSA, pH 7.4) at 1.0 × 10^7^ cells/ml \[[@B26]\]. \[^32^P\]-Orthophosphate was added to the neutrophil suspension at 100 µCi/10^7^ cells and the cells were incubated at 37°C for 60 min with gentle mixing every 10 min. After 3 washes, calcium ion, phosphate-free buffer was added to the pellet (1.0 × 10^7^ cells/ml).

Neutrophils (1.0 × 10^7^ cells/ml × 300 µl) were suspended in phosphate-free buffer (695 µl; 10 mM HEPES, 137 mM sodium chloride, 5.4 mM potassium chloride, 1.26 mM calcium chloride, 5.6 mM D-glucose, 0.8 mM magnesium chloride, and 0.025% BSA, pH 7.4) \[[@B26]\]. After preincubation for 1 min at 37°C, the reaction was started by adding 5 µl of stimulator dissolved in methanol (1.6 mM PLG-OOH, 200 µM fMLP or 640 nM PMA). The reaction was stopped by centrifugation (12,000 rpm × 10 s) at the times described in the figure legends, and the supernatant was removed. Two hundred microliters of lysis buffer (200 µM phenylmethylsulfonyl fluoride, 3 µM leupepsin, 2 µM pepstatin, 1 µM staurosporine, 100 nM calysurin A, 100 µM *o*-vanadate, 150 mM NaCl, and 1% NP-40 in 50 mM Tris-HCl (pH 8); protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany) plus staurosporine) was added to the pellet and mixed vigorously for 1 min. After centrifugation, 5 µl of rabbit polyclonal anti-p47^*phox*^ antibody was added to the supernatant and the solution was rotated at 4°C for 1.5 h. Eighty microliters of 10% protein A sepharose CL-4B in NET gel buffer (Tris buffer containing NP-40, EDTA, and gelatin) was added and the solution was rotated at 4°C for 1 h. After 3 washes of the precipitate with lysis buffer, 40 µl of SDS-PAGE sample buffer was added and the samples were boiled at 100°C for 5 min. Electrophoresis was performed with a 10% polyacrylamide gel. A low molecular weight marker (Bio-Rad Laboratories, Inc., Herculus, CA) was used. Phosphorylated protein was detected using autoradiography.

Results
=======

Synthesis of various molecular species of DAG, DAG-OOH, and DAG-OH
------------------------------------------------------------------

We first synthesized various molecular species of DAG-OOH to investigate which molecular species of DAG-OOH activate neutrophils. PC-OOH was formed by the oxidation of PC with lipoxygenase and it was hydrolyzed with PLC to form DAG-OOH, as described in the "Materials and Methods" section (Fig. [1](#F1){ref-type="fig"}). 1,3-LLG-OOH was synthesized by autoxidation of 1,3-LLG with *a*-tocopherol. The structures of various molecular species of DAG-OOH used in the present study are shown in Fig. [2](#F2){ref-type="fig"}. Various molecular species of DAG-OH were synthesized via the hydrolysis of PC-OH, which was formed by the reduction of PC-OOH with sodium borohydride, with PLC (Fig. [1](#F1){ref-type="fig"}). Various molecular species of DAG were synthesized by the hydrolysis of PC with PLC (Fig. [1](#F1){ref-type="fig"}).

Activation of neutrophils by various molecular species of DAG, DAG-OOH, or DAG-OH
---------------------------------------------------------------------------------

The activation of neutrophils by various molecular species of DAG, DAG-OOH, or DAG-OH (4 µM each) was investigated (Fig. [3](#F3){ref-type="fig"}). Activation of neutrophils was evaluated using maximum MCLA-dependent luminescence intensity, which represents the maximum rate of O~2~^·−^ formation. No light emission was observed when only methanol was added to the neutrophil suspension (data not shown). The DAG-OOH or DAG-OH composed of linoleate hydroperoxide (hydroxide) was a more powerful activator of neutrophils than that composed of arachidonate hydroperoxide (hydroxide) (Fig. [3](#F3){ref-type="fig"}A, B). The activation of neutrophils by 1,3-LLG-OOH was weaker than that by any 1,2-DAG-OOH, as reported previously \[[@B18]\]. The difference in the fatty acid composition of DAG species, including 1,2-dioleoylglycerol (OOG), which is widely used as a PKC activator, did not affect the maximum luminescence intensity (Fig. [3](#F3){ref-type="fig"}C). PLG-OOH was the strongest activator of neutrophils among the various DAG, DAG-OOH, and DAG-OH species tested in the present study. Moreover, the activation of neutrophils by PLG-OOH was significantly stronger than that by 1-oleoyl-2-acetylglycerol (OAG), which is generally used as a stimulator of cells (Fig. [3](#F3){ref-type="fig"}A). Based on these findings, PLG-OOH was used in the subsequent experiments. The ability to activate neutrophils among molecular species containing the same fatty acid composition was as follows; DAG-OOH\>DAG-OH≥DAG. This order did not change when 8 µM of stimulator was used (data not shown). No significant difference between the activation of PKC by DAG-OOH and that by DAG-OH *in vitro* has been reported \[[@B12]\]. Further studies are needed to elucidate why different results were obtained *in vitro* versus *ex vivo*.

Phosphorylation of p47^phox^ in neutrophils by the stimulation of DAG-OOH
-------------------------------------------------------------------------

The activation of PKC in neutrophils by DAG-OOH was reconfirmed. p47^*phox*^ is a cytosolic factor of NADPH oxidase, and known as a substrate of PKC \[[@B21]\]. When only methanol (0.5% to solution) was added to the neutrophil suspension, p47^*phox*^ was not phosphorylated after 2 min at 37°C (Fig. [4](#F4){ref-type="fig"}). p47^*phox*^ was phosphorylated in 8 µM PLG-OOH-stimulated neutrophils, as in PMA (3 nM)-stimulated or fMLP (1 µM)-stimulated neutrophils (Fig. [4](#F4){ref-type="fig"}).

The phosphorylated p47^*phox*^ at 1 min after stimulation decreased at 2 min in both fMLP (1 µM)-stimulated and PLG-OOH (8 µM)-stimulated neutrophils (Fig. [5](#F5){ref-type="fig"}A). This change was comparable to that in MCLA-dependent luminescence intensity (1 µM fMLP; Fig. [5](#F5){ref-type="fig"}B, 8 µM PLG-OOH; Fig. [5](#F5){ref-type="fig"}C). These results suggest that p47^*phox*^ was phosphorylated by PKC in PLG-OOH-stimulated neutrophils. In fact, the production of O~2~^·−^ was inhibited by serine/threonine kinase inhibitors and PKC inhibitors, such as staurosporine, H-7, and chelerythrine \[[@B18]\].

Discussion
==========

The activation of human neutrophils by various molecular species of DAG, DAG-OOH, and DAG-OH was investigated in the present study. In order of the amount of PC in rat liver, the species ranked as follows; SAPC (16.1%)\>SLPC (14.8%)\>PLPC (14.1%)\>PAPC (9.7%) \[[@B27]\]. In terms of the amount of fatty acid in the phospholipids of mammalian cells, fatty acid ranked as follows; palmitate (33%)\>oleate (25%)\>stearate (12%)\>linoleate (10%)\>arachidonate (8%) (human neutrophil phospholipids) \[[@B28]\], palmitate (33%)\>arachidonate (19%)\>stearate (16%)\>oleate (13%)\>linoleate (7%) (human coronary artery phospholipids) \[[@B29]\], and linoleate (25%)\> stearate (24%)\>palmitate (17%)\>arachidonate (16%) (rat heart phosphatidylcholine at 100 days old) \[[@B30]\]. Almost all phospholipids in mammalian cells have a saturated fatty acid at the *sn*-1 position and an unsaturated fatty acid at the *sn*-2 position. Oleate is not easily oxidized by free radicals. Therefore, diacylglycerols with palmitate or stearate at the *sn*-1 position and linoleate or arachidonate at the *sn*-2 position were used in the present study. Although all molecular species of DAG, DAG-OOH, and DAG-OH containing these fatty acids activated human neutrophils, PLG-OOH was the most potent activator.

Human neutrophils have PKCα and PKCδ \[[@B31]\]. We also detected these PKC isoforms in neutrophils in the Western blot analysis (data not shown). Recently, it was found that DAG-OOH activated various PKC isoforms *in vitro*, but only PKCα and PKCδ were activated by DAG-OOH more strongly than by DAG (our unpublished data). These PKC isoforms may be involved in the activation of neutrophils by PLG-OOH.

Calcium, phospholipid-independent activity of bovine brain PKC is increased by oxidation of the regulatory domain of PKC by hydrogen peroxide or periodate \[[@B32], [@B33]\]. Even PKC in cells (PKCγ in N/N1003A cells \[[@B34]\] and PKCδ in COS-7 cells \[[@B35]\]) was oxidized by hydrogen peroxide and was activated. Oxidation of PKC by PLG-OOH might cause neutrophil activation in the present study. However, 8 µM PC-OOH, linoleate hydroperoxide, and hydrogen peroxide did not induce production of O~2~^·−^ by human neutrophils in our previous study \[[@B18]\]. Moreover, we reconfirmed the activation of PKC in neutrophils by PLG-OOH using p47^*phox*^ phosphorylation in the present study. Therefore, PLG-OOH might activate PKC in neutrophils directly. PKCδ is activated via tyrosine phosphorylation by high concentrations (mM) of hydrogen peroxide \[[@B36], [@B37]\]. Further study is needed to clarify whether tyrosine residues of PKCδ in neutrophils are phosphorylated by PLG-OOH stimulation.

It has been suggested that oxidative stress causes disease, cancer, and aging through the accumulation of oxidative damage, including the oxidation of DNA, lipids, and proteins \[[@B15]\]. However, there is little direct evidence that oxidative damage is the cause of various diseases, although much indirect evidence has been reported. We previously proposed that DAG-OOH, formed by the actions of PLC after the oxidation of biomembrane phospholipids by free radicals \[[@B14]\], activates PKC, and causes diseases such as cancer, since this signal is not regulated by receptors (Fig. [6](#F6){ref-type="fig"}) \[[@B12], [@B16]\]. In the present study, we confirmed that PLG-OOH activates intracellular PKC. This result suggests that our proposal occurs in biological systems.

The activation of neutrophils is involved in inflammatory diseases (for example; acute inflammatory liver injury \[[@B38]\] and chronic inflammatory airway disease \[[@B39]\]). PKC is activated under oxidative stress \[[@B40]\] (for example; cardiac reperfusion \[[@B41]\], diabetic nephropathy \[[@B42]\] and ischemia reperfusion of skeletal muscle \[[@B43]\]). In some cases, PLG-OOH may activate PKC.

In summary, various molecular species of DAG, DAG-OOH and DAG-OH were synthesized. All the DAG-OOHs tested in the present study activated neutrophils, but PLG-OOH was the most potent activator. When PLG-OOH stimulated neutrophils, O~2~^·−^ was produced via the phosphorylation of p47^*phox*^ by PKC. These results suggest that PLG-OOH activates PKC in cells. Therefore, PLG-OOH, produced via an uncontrolled process, can act as a second messenger in the progression from oxidative stress-induced damage to inflammatory disease (Fig. [6](#F6){ref-type="fig"}).
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![Procedures for the synthesis of diacyglycerol, diacylglycerol hydroperoxide, and diacylglycerol hydroxide.](jcbn2007040f01){#F1}

![Structures of various molecular species of diacylglycerol hydroperoxide used in the present study.](jcbn2007040f02){#F2}

![Activation of neutrophils by diaclyglycerol hydroperoxides (A), diacylglycerol hydoxides (B), or diaclyglycerols (C). The maximum MCLA-dependent luminescence intensity was measured as the rate of superoxide anion formation from neutrophils (2.5 × 10^4^ cells/ml). The concentration of each stimulator used here was 4 µM. One micromolar MCLA was used in this experiment. Results are expressed as means ± standard deviations (*n* = 5). Abbreviations used in the figures are as follows; PAG, 1-palmitoyl-2-arachidonoylglycerol; PLG, 1-palmitoyl-2-linoleoylglycerol; SAG, 1-stearoyl-2-arachidonoylglycerol; SLG, 1-stearoyl-2-linoleoylglycerol; 1,3-LLG, 1,3-dilinoleoylglycerol; OAG, 1-oleoyl-2-acetylglycerol; OOG, 1,2-dioleoylglycerol; -OOH, hydroperoxide; -OH, hydroxide.](jcbn2007040f03){#F3}

![Phosphorylation of p47^*phox*^ in neutrophils (3 × 10^6^ cells/ml) activated by various stimulators. Lane 1; Methanol (0.5% of solution) was used in the control experiment (2 min). Lane 2; Three nanomolar 4β-phorbol-12β-myristate-13α-acetate (PMA) was used, and stimulation was stopped at 5 min. Lane 3; One micromolar *N*-formyl-methionyl-1-leucyl-phenylalnine (fMLP) was used, and stimulation was stopped at 2 min. Lane 4; Eight micromolar 1-palmitoyl-2-linoleoylglycerol hydroperoxide (PLG-OOH) was used, and stimulation was stopped at 2 min.](jcbn2007040f04){#F4}

![Time course of p47^*phox*^ phosphorylation in neutrophils (3 × 10^6^ cells/ml) stimulated by 1 µM *N*-formyl-methionyl-1-leucyl-phenylalnine (fMLP) or 8 µM 1-palmitoyl-2-linoleoylglycerol hydroperoxide (PLG-OOH) (A). Time-dependent change in MCLA-dependent luminescence from 1 µM fMLP-stimulated neutrophils (2.5 × 10^4^ cells/ml) (B) and 8 µM PLG-OOH-stimulated neutrophils (2.5 × 10^4^ cells/ml) (C).](jcbn2007040f05){#F5}

![Proposed mechanism for free radical-induced unregulated signal transduction.](jcbn2007040f06){#F6}
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